We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

54 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

223% more capital inflows, than outflows

Capital inflows: $825K | Capital outflows: $255K

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

10% more funds holding

Funds holding: 49 → 54 (+5)

0.33% more ownership

Funds ownership: 12.53% → 12.86% (+0.33%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

Holders
54
Holders Change
+5
Holders Change %
+10.2%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$279K
2
Sargent Investment Group
Sargent Investment Group
Maryland
+$194K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$110K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$77.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$26.5K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$51.8K
2
Virtu Financial
Virtu Financial
New York
-$51.8K
3
Private Advisor Group
Private Advisor Group
New Jersey
-$47.1K
4
IIA
IPG Investment Advisors
California
-$45K
5
Jane Street
Jane Street
New York
-$23K

MTNB Hedge Fund Activity: Q3 2022 in Review

54 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2022, worth a combined $18M — down 16% from $21.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MTNB positions and 4 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.

The largest buyer was LPL Financial, adding an estimated $279K. The largest seller was BlackRock, cutting an estimated $51.8K.

  • 54 institutional investors held Matinas BioPharma (MTNB) as of Q3 2022, up from 49 in Q2 2022.
  • Funds reported $18M of Matinas BioPharma stock for Q3 2022, down 16% quarter-over-quarter.
  • 9 funds opened new Matinas BioPharma positions in Q3 2022 and 4 closed out, a net change of +5 holders.
  • The largest Matinas BioPharma buyer in Q3 2022 was LPL Financial, an estimated $279K added.
  • The largest Matinas BioPharma seller in Q3 2022 was BlackRock, an estimated $51.8K sold.

Based on aggregated 13F filings for Q3 2022.